Myovant CEO Says Buoyant IPO Reflects High Interest In Women's Health

Recently created biotech Myovant has floated on the New York Stock Exchange to raise capital to progress its two lead candidate therapies; one for women's health conditions and another for prostate, and says Pfizer's sizable stake in the IPO reflects rising interest in these therapy areas.

SC1610_Womens Health_1200x675

The rising attractions of women's health care to investors and pharma alike was underscored by Myovant Sciences Ltd.'s successful initial public offering Oct 27 which raised some $218m and included hefty investments from Pfizer Inc. and Swiss investment firm BB Biotech.

The Bermuda-based clinical-stage biopharma is developing treatments for uterine fibroids and endometriosis that it has in-licensed from Japan-based Takeda...

More from Business

More from Scrip